Key Findings
ISM9546 has been nominated as a preclinical candidate (PCC) for the treatment of autoimmune diseases, specifically inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). In animal models of acute colitis, the compound significantly reduced the Disease Activity Index (DAI) within days of treatment. Histopathological analysis confirmed a reduction in pathology scores by approximately 60%, showing substantial decreases in intestinal tissue injury and inflammatory cell infiltration.
Technical Details
The compound was developed using the Pharma.AI solution and the Chemistry42 generative chemistry platform, which utilizes over 40 generative models and multiple predictive modules. The design process focused on de novo fragment growing based on the target-ligand complex structure and key binding-pocket residues.
- Potency: Demonstrated sub-nanomolar VAV1 degradation potency in cellular assays.
- Safety Profile: Peripherally restricted profile with low brain exposure confirmed via in vitro MDCKII-MDR1 assays and in vivo tissue distribution studies, reducing CNS risks.
- Tolerability: 14-day rodent and non-human primate toxicity evaluations showed broad safety margins; proteomics profiling indicated no off-target protein depletion.
- Pharmacokinetics: Features a balanced elimination half-life to maintain peripheral target engagement while allowing recovery of adaptive immune responses during acute infections.
Background & Context
VAV1 (Vav guanine nucleotide exchange factor 1) is critical for immune cell signaling, controlling proliferation and cytokine secretion. Due to the absence of a classic small-molecule binding pocket, VAV1 was previously considered “undruggable” until the emergence of molecular glue therapies. ISM9546 represents the 11th PCC nominated by Insilico Medicine in the first 10 months of 2026 alone.
Significance & Outlook
The nomination of ISM9546 demonstrates the ability of generative AI to systematically address challenging targets and complex mechanisms of action. By integrating molecular generation and multi-parameter optimization, Insilico Medicine aims to reduce costs and increase the speed of developing therapies for chronic illnesses and aging-related hallmarks.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
